Amgen Inc. AMGNhas announced full results from the phase IIIb study on its anti-CGRP receptor antibody, Aimovig (erenumab), which once again demonstrates a significant reduction in migraine frequency. The company is looking to get Aimovig (140mg) approved for treatment of episodic migraine in patients with a previous experience of two to four preventive treatment failures due to lack of efficacy or intolerable side effects.
The phase III LIBERTY study randomized 246 patients with the aforementioned indication to receive Aimovig 140 mg or placebo for 12-weeks. Data from the study demonstrated reduction in episodic migraines by at least half in 30% of Aimovig treated patients with multiple treatment failures compared with 14% of patients treated with placebo.
Moreover, over 97% of Aimovig patients completed the double-blind phase of the LIBERTY trial. No adverse events were found that might lead to discontinuation of treatment in the Aimovig group. Outcomes from the study will be presented at the 70th annual meeting of the American Academy of Neurology in Los Angeles.